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Abstract. 
 
Activation of integrins upon binding to ex-
tracellular matrix proteins is believed to be a crucial 
step for the regulation of cell survival and proliferation. 
We have used integrin 
 
a
 
1-null mice to investigate the 
role of this collagen receptor in the regulation of cell 
growth and survival in vivo. 
 
a
 
1-deficient animals, which 
are viable and fertile, have a hypocellular dermis and a 
deficiency in dermal fibroblast proliferation as em-
bryos. In vitro analysis of 
 
a
 
1-null embryonic fibroblasts 
has revealed that their proliferation rate is markedly re-
duced when plated on collagenous substrata, despite 
normal attachment and spreading. Moreover, on the 
same collagenous matrices, 
 
a
 
1-null fibroblasts fail to re-
cruit and activate the adaptor protein Shc. The failure 
to activate Shc is accompanied by a downstream defi-
ciency in recruitment of Grb2 and subsequent mitogen-
activated protein kinase activation. Taken together 
with the growth deficiency observed on collagens, this 
finding indicates that the 
 
a
 
1
 
b
 
1 is the sole collagen re-
ceptor which can activate the Shc mediated growth 
pathway. Thus, integrin 
 
a
 
1 has a unique role among the 
collagen receptors in regulating both in vivo
 
 
 
and in 
vitro cell proliferation in collagenous matrices.
Key words:
 
a
 
1
 
b
 
1 integrin • collagen • proliferation • 
signal transduction • dermis
 
I
 
ntegrins
 
 are transmembrane heterodimeric receptors
for extracellular matrix (ECM)
 
1
 
 molecules (Hynes,
1992). They are composed of 
 
a
 
 and 
 
b
 
 subunits that
heterodimerize to produce 
 
.
 
20 different receptors. One
family of integrins, which all have the 
 
b
 
1 subunit in com-
mon, include high affinity receptors for many ECM pro-
teins including fibronectin, laminin, and the collagens.
Three members of this family are known to be the major
receptors for collagens, namely 
 
a
 
1
 
b
 
1, 
 
a
 
2
 
b
 
1, and 
 
a
 
3
 
b
 
1
(Yamamoto and Yamamoto, 1994; Gardner et al., 1996).
All three of these receptors are expressed by fibroblasts,
and they seem to regulate different functions. Integrin
 
a
 
1
 
b
 
1, for example, appears to regulate collagen synthesis,
whereas 
 
a
 
2
 
b
 
1 mediates collagen gel contraction (Schiro et
al., 1991; Langholz et al., 1995; Broberg and Heino, 1996).
Integrin 
 
a
 
1
 
b
 
1 is widely expressed in the adult animal,
being found in visceral and some vascular smooth muscle,
liver, microvascular endothelium, activated lymphocytes,
and dermis (see references cited in Gardner et al., 1996).
During embryonic development, 
 
a
 
1 is first expressed in
trophoblast immediately after implantation (Sutherland
et al., 1993), suggesting an essential role of this molecule
during early stages of development. To analyze the role of
 
a
 
1 integrin during mouse formation, we have generated
mice deficient in integrin 
 
a
 
1 by gene targeting (Gardner
et al., 1996). This disruption prevents the formation of the
 
a
 
1
 
b
 
1 receptor without altering other 
 
b
 
1 integrin het-
erodimers. Animals homozygous for the disruption de-
velop normally and are fertile, indicating that despite its
prominent expression during development, 
 
a
 
1 integrin is
not essential for formation of the adult mouse. Using em-
bryonic fibrobasts derived from mutant animals, we have
shown that 
 
a
 
1 uniquely confers on fibroblasts the ability to
adhere and migrate on collagen IV, while being only one
of three integrin collagen type I receptors present on fi-
broblasts, together with 
 
a
 
2
 
b
 
1 and 
 
a
 
3
 
b
 
1. Recent studies
have also implicated DDR1 and 2, “orphan” tyrosine ki-
nase receptors, as receptors for collagens (Shrivastava et
al., 1997; Vogel et al., 1997).
The interaction between integrins and their ligands, be-
sides mediating cell adhesion, plays a role in a number of
cellular processes, including cell differentiation (Adams
and Watt, 1993), cell cycle progression (Giancotti, 1997),
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and cell survival (Frisch and Ruoslahti, 1997). The regula-
tion of these different events requires the activation of
specific cellular targets, including protein kinase C (Clark
and Brugge, 1995), PI3-OH kinase (Khwaja et al., 1997),
and the small GTPase Rho (Schwartz et al., 1996). More-
over, there is evidence that integrins activate shared as
well as subgroup-specific signaling pathways that contrib-
ute to organization of the cytoskeleton and activation of
the mitogen-activated protein kinase (MAPK) cascades,
thereby influencing immediate early gene expression
(Clark and Hynes, 1997; Giancotti, 1997). Recent studies
have indicated that a class of integrins that includes the
 
a
 
1
 
b
 
1, 
 
a
 
5
 
b
 
1, 
 
a
 
6
 
b
 
4, and 
 
a
 
v
 
b
 
3 receptors, is coupled to the
Ras–MAPK signaling pathway by the adaptor protein Shc
(Maniero et al., 1995; Wary et al., 1996; Maniero et al.,
1997). Adhesion mediated by Shc-linked integrins pro-
motes cell survival and progression through the G1 phase
of the cell cycle in response to mitogenic growth factors,
whereas adhesion mediated by other integrins results in
exit from the cell cycle and, in certain cases, cell death
(Wary et al., 1996; Maniero et al., 1997). These in vitro
studies suggest that integrin 
 
a
 
1
 
b
 
1 may regulate cell sur-
vival and growth in response to ECM components. We
have used integrin 
 
a
 
1–null mice to investigate the role of
this collagen receptor in the regulation of cell survival and
proliferation in vivo. The observation that 
 
a
 
1-null dermis
is hypocellular, prompted us to analyze fibroblasts from
control and integrin 
 
a
 
1–deficient mice, and to compare
their growth and survival in response to ECM. 
 
a
 
1-null fi-
broblasts proliferate less than their normal counterparts
both in vivo and in vitro, suggesting that survival and pro-
liferation on collagenous substrata are events mediated
specifically and uniquely by activation of integrin 
 
a
 
1
 
b
 
1.
These results suggest that 
 
a
 
1
 
b
 
1 has, among many integrin
and non-integrin collagen receptors, a unique signaling
function in vivo.
 
Materials and Methods
 
Cell Culture and Matrix Components
 
Mouse embryonic fibroblasts (EFs) were isolated from wild-type and 
 
a
 
1-
null E 14.5 embryos by trypsinization (Li et al., 1992). All cells were used
for in vitro studies at matched passage numbers 3 or 4. Cells were cultured
in DME supplemented with 2% or 10% FCS (GIBCO BRL, Gaithers-
burg, MD). Matrix components used in the study were bovine skin col-
lagen I (Vitrogen 100; Collagen Corp., Palo Alto, CA), human placental
collagen IV (Sigma Chemical Co., St. Louis, MO), human fibrinogen (gift
of Z. Ruggeri, The Scripps Research Institute, La Jolla, CA), and bovine
plasma fibronectin (GIBCO BRL).
 
Evaluation of Fibroblast Density in the Dermis
 
129Sv/ter wild-type and integrin 
 
a
 
1-null mice (6-, 12-, and 24-wk old) were
killed by cervical dislocation. The dorsal skin was shaved, removed, fixed
in formalin, and then embedded in paraffin. Sections were stained with
hematoxylin and eosin, and the number of dermal nuclei was determined
by random evaluation of six high power field views of normal, as well as
 
a
 
1-null dermis.
 
Measurement of In Vivo Proliferative Index by
PCNA Labeling
 
Integrin 
 
a
 
1–null and –positive control mouse embryos at day 16.5 of ges-
tation, were obtained from timed matings. Embryos were fixed in forma-
lin and paraffin embedded. For proliferating cell nuclear antigen (PCNA)
staining, transverse midsections of three wild-type, as well as three 
 
a
 
1-
deficient embryos, were stained by using the mouse monoclonal IgG2a
antibody PC10 (Zymed Laboratories, Inc., South San Francisco, CA) at a
dilution of 1:200. Biotinylated secondary anti–mouse antibody and avidin/
biotin-HRP–conjugated complex were used to detect bound antibody.
Sections were then counterstained with hematoxylin and the dermal pro-
liferative index (PCNA-positive cells/total number of counted cells 
 
3 
 
100)
was determined by random evaluation of 12 40
 
3
 
 field views of dermis of
each embryo. At least 900 cells around the entire circumference of the
dermis of each embryo were thus counted.
For wound healing experiments, 1-cm dorsal full thickness, cutaneous
incisions were made and immediately closed with interrupted 6/0 prolene
sutures in four wild-type and four age-matched 
 
a
 
1-null animals. 12 d after
the incision, animals were killed and the dorsal skin was shaved, removed,
fixed in formalin, and then paraffin embedded. Sections were then sub-
jected to PCNA staining as described above. Fibroblasts in three 40
 
3
 
fields encompassing the wound were counted, and the proliferation index
expressed as number of PCNA-positive nuclei/total fibroblast number. At
least 300 cells in each wound were counted.
 
Cell Proliferation Assay
 
Control and integrin 
 
a
 
1-null EFs were obtained from E13.5 embryos, ac-
cording to the method of Li et al. (1992). Cells were detached from culture
dishes by trypsin, washed, resuspended in DME containing 2% or 10%
FCS, and then plated at the density of 10 
 
3 
 
10
 
4
 
 cells on 24-well plates un-
coated, or coated with fibrinogen (10 
 
m
 
g/ml), collagen I (100 
 
m
 
g/ml), or a
mixture of collagen I (100 
 
m
 
g/ml) and IV (30 
 
m
 
g/ml). Fibrinogen solution
was prepared in PBS, while the solutions containing collagen I were pre-
pared in 0.1 M acetic acid, as described by Koyama et al. (1996). Cells
were trypsinized and counted every 24 h, for a total of 72 h.
 
Measurement of In Vitro Proliferative Index by BrdU 
Labeling and FACS
 
®
 
To evaluate the proliferative index, control and integrin 
 
a
 
1–deficient EFs
were plated in presence of 2% FCS, at a density of 5 
 
3
 
 10
 
4
 
 cells on 16-well
tissue culture chamber slides (Nunc, Inc., Naperville, IL) that were un-
coated or coated with fibrinogen (10 
 
m
 
g/ml), collagen I (100 
 
m
 
g/ml), or a
mixture of collagens I (100 
 
m
 
g/ml) and IV (30 
 
m
 
g/ml). After 24 h, cells
were labeled with 10 
 
m
 
M 5
 
9
 
-bromo-2
 
9
 
-deoxy-uridine (BrdU; Sigma Chem-
ical Co.), and incubated for a further 24 h. Cells were then washed, fixed,
and stained with anti-BrdU mAbs (Sigma Chemical Co.), followed by
biotinylated secondary anti–mouse antibody and avidin/biotin-HRP–con-
jugated complex (Vector Laboratories, Burlingame, CA). The BrdU la-
beling index (positive cells/total number of counted cells 
 
3 
 
100) was de-
termined by random evaluation of 10 40
 
3
 
 fields, counting a minimum of
200 cells. For FACS
 
®
 
 analysis, 3 
 
3 
 
10
 
5
 
 serum-starved cells were plated on
6-well plates coated with fibronectin (10 
 
m
 
g/ml), fibrinogen (10 
 
m
 
g/ml) or
collagen I (100 
 
m
 
g/ml) in 2% FCS. After 12 h, they were trypsinized and
fixed in 70% ethanol. Cells were stained with PBS/0.1% Triton X-100/0.2
mg/ml RNase A/20 
 
m
 
g/ml propidium iodide, and analyzed on a Becton
Dickinson FACScan
 
®
 
 machine. S phase measurements were obtained us-
ing the Mod Fit LT v.2 program (Verity Software, Topsham, ME).
 
Measurement of In Vitro Apoptotic Index by
DAPI Labeling
 
To evaluate the effect of ECM proteins on cell survival, control and inte-
grin 
 
a
 
1–deficient EFs were either kept in suspension, or plated in absence
of serum, at the density of 7 
 
3 
 
10
 
4 
 
cells on coverslips coated with fibrino-
gen (10 
 
m
 
g/ml), collagen I (20 
 
m
 
g/ml), or a mixture of collagen I (20 
 
m
 
g/ml)
and IV (10 
 
m
 
g/ml). After 16 h, coverslips were washed with PBS to re-
move unattached cells, and then fixed and stained with 0.5 
 
m
 
g/ml DAPI
(Sigma Chemical Co.)/PBS/0.1% Triton X-100. Chromatin condensation
was used as morphological index for apoptotic cells. The apoptotic label-
ing index (cells with condensed chromatin/total number of counted cells 
 
3
 
100) was determined by random evaluation of 5–10 40
 
3 
 
fields, counting a
minimum of 300 cells.
 
In Vitro Immunoprecipitation Assay
 
Cell lysates were prepared according to the procedure described by Wary
et al., 1996. Briefly, control and integrin 
 
a1–null EFs were growth factor
starved for 8 h, and subsequently trypsinized. Cells were then resuspendedPozzi et al. a1b1 Integrin and Proliferation 589
in DME containing 0.1% BSA and kept at room temperature for 30 min.
They were then either left in suspension or plated on dishes coated with fi-
bronectin (10 mg/ml), collagen I (20 mg/ml), or a mixture of collagen I (20
mg/ml) and IV (10 mg/ml) all diluted in PBS. After 1 h at 378C, the cells
were washed with PBS, scraped with a rubber spatula in 50 mM Hepes,
pH 7.5, 150 mM NaCl, 1% Triton X-100, and then centrifuged at 14,000
rpm at 48C for 10 min. Protein concentration was determinded using the
micro BCA assay (Pierce Chemical Co., Rockford, IL) with BSA as the
standard. Immunoprecipitation and immunoblotting were performed as
described by Maniero et al. (1995). Briefly, lysates containing equal
amount of proteins were immunoprecipitated with affinity-purified anti-
Shc polyclonal antibody (Maniero et al., 1995), and subjected to immuno-
blotting with anti-phosphotyrosine mAb RC-20H (Transduction Labora-
tories, Lexington, KY), anti-Grb2 polyclonal antibody (C-23; Santa Cruz
Biotechnology, Santa Cruz, CA), and anti-Shc polyclonal antibody. Nitro-
cellulose-bound antibodies were detected by chemiluminescence with en-
hanced chemiluminescence (ECL; Amersham, Life Sciences, Little Chal-
font, UK). To examine Erk activity, cell lysates containing equal amount
of proteins were immunoprecipitated with anti-Erk2 polyclonal antibody
C-14 (Santa Cruz Biotechnology) and subjected to in vitro kinase assay in
50 mM Tris, pH 7.5, 10 mM MgCl2 containing 5 mCi of [g32P]ATP (4,500
Ci/mmol; ICN Biomedicals, Inc., Costa Mesa, CA) and 2.5 mg of myelin
basic protein (Sigma Chemical Co.).
Results
a1-deficient Dermis Is Hypocellular
Histological analysis of skin sections from wild-type and
a1-deficient mice did not reveal any substantial differ-
ences in dermal morphology and thickness (Fig. 1 A).
However, we observed that the number of dermal nuclei
was reduced in the a1-null skin when compared with the
wild-type group (Fig. 1 A). To quantify this difference,
pairs of wild-type and knockout skins obtained from 6-,
12-, and 24-wk-old 129Sv/ter mice were stained with hema-
toxylin and eosin, and the number of dermal nuclei was
determined by random evaluation of six high power field
views of dermis. The number of dermal nuclei in a1-null
dermis was reduced at all stages examined as compared
with the wild-type dermis (Fig. 1 B). To assess whether the
difference in cell number was due to dermal fibroblasts,
rather than dermal lymphocytes, the dermis of both con-
trol and a1-deficient animals were stained with CD5, a
specific T-lymphocyte marker. No CD5 dermal staining
was observed in the dermis of wild-type or a1-null animals
(data not shown), suggesting that dermal fibroblasts rather
than lymphocytes account for the difference in cell num-
ber observed in the two groups.
The observation that there are fewer fibroblasts in the
dermis of a1-null animals than in the control group sug-
gests the possibility of a deficiency in survival or prolifera-
tion of a1-null fibroblasts in the dermis.
a1-null Embryonic Fibroblasts Show Marked 
Reduction in Proliferation Compared with Their
Wild-Type Counterparts
To test the hypothesis that a1b1 integrin delivers a growth
signal, the proliferative index of wild-type and a1-deficient
dermal fibroblasts was assessed by staining both embry-
onic and adult skin with antibodies to PCNA. PCNA is a
DNA polymerase e– and g–associated protein, which is
bound tightly to DNA only during S phase (Toschi and
Bravo, 1988); in formalin-fixed, paraffin-embedded tissues
PCNA is preferentially retained in S phase cells. Whereas
results from PCNA staining are not numerically compara-
ble to other methods of estimating S phase fraction, they
do provide robust comparisons between similarly pro-
cessed samples (Holt et al., 1997). As expected, there was
no appreciable proliferation in sections of adult dermis of
either genotype (data not shown). Analysis of 16.5-d-old
embryos, however, (Fig. 2 A) revealed a marked reduction
in the proliferative index of a1-null dermis as compared
with the wild-type (Fig. 2 B).
To induce fibroblast proliferation in adult dermis 1-cm
full-thickness, dorsal cutaneous incisions were generated
in age-matched wild-type and a1-null animals, and al-
lowed to heal by primary intention. Sections of 12-d-old
wounds were stained with antibodies to PCNA (Fig. 3 A).
No differences in the proliferative index of dermal fibro-
blasts of either genotype were evident in the wounded ar-
eas (Fig. 3 B). We also investigated the proliferative index
of different embryonic, as well as adult tissues known to
express a1b1 integrin, such as liver hepatocytes (Gullberg
et al., 1990) and smooth muscle. No appreciable differ-
ences were observed between wild-type and a1-null em-
bryos or adults in these tissues.
Figure 1. Fibroblast density in dermis of wild-type and a1-deficient animals. (A) Representative sections of wild-type (WT) and a1-defi-
cient (KO) 6-wk-old skin stained with hematoxylin and eosin. The a1-deficient skin has apparently normal architecture but reduced num-
bers of nuclei in the dermis. (B) Counts of dermal nuclei in pairs of wild-type and knockout skin obtained from 6-, 12-, and 24-wk-old 129
Sv/ter mice. Each pair of bars represents one pair of apposed sections of back skin sectioned at 5 mm. Note the lower number of dermal
nuclei in a1-null dermis compared with that observed in wild-type samples. Bars and errors show mean and standard deviation of counts
of dermal nuclei in six high power field views of dermis. Differences between wild-type and a1-null groups were significant with P , 0.05
by Student’s t test in each case. Bar, 100 mm.The Journal of Cell Biology, Volume 142, 1998 590
The finding on embryonic dermis prompted us to deter-
mine whether the differences in cell survival and prolifera-
tion observed in vivo were due to the interaction of spe-
cific ECM components with the a1b1 receptor. Therefore,
we analyzed the growth profile of fibroblasts in vitro, by
using embryonic fibroblasts, derived from control and a1-
null animals, plated in the presence of low or high serum
concentration on different substrata (Fig. 4, A and B).
Whereas both wild-type and a1-null EFs showed similar
growth profiles on tissue culture plastic, fibrinogen, (Fig.
4, A and B) or fibronectin (not shown), on collagen sub-
strata a1-deficient EFs showed a marked reduction in pro-
liferation in comparison to wild-type cells. Similar defi-
ciency in a1-null cell growth was seen when cells were
plated on collagen IV alone (not shown). As expected, the
differences in cell growth on collagen substrata were most
pronounced in growth media containing 2% serum, and
were less pronounced in the presence of 10% serum (Fig. 4
B), where both growth factors and ligands for av and a5
integrins, vitronectin and fibronectin, were more abun-
dant. Attempts to grow EFs in defined media in the ab-
sence of serum but containing bFGF and EGF (Wary et
al., 1996) were unsuccessful.
The differences in fibroblast proliferation on collagens
was also confirmed by BrdU incorporation and anti-BrdU
staining. After 48 h of culture in 2% serum, a similar pro-
portion of wild-type and a1-deficient EFs was BrdU posi-
tive when plated on tissue culture plastic, or fibrinogen
(Fig. 5 A). In contrast, a marked reduction in BrdU incor-
poration was observed in a1-null EFs plated on collagen I
(Fig. 5 A), or a mixture of collagen I and IV (Fig. 5 A).
Similar results were observed when serum-starved cells
were plated on collagenous or non-collagenous substrata
in presence of 2% FCS, and then analysed by FACS® after
12 hours (Fig. 5 B).
While it is clear that apoptosis occurs via distinct cellular
pathways, it is a frequent observation that circumstances
preventing cell proliferation are associated with an in-
crease in cell death. To determine whether a1-null EFs
were more susceptible to apoptosis than their wild-type
counterparts, cells were plated on different substrata, or
kept in suspension, in the absence of serum, and the apop-
totic index was determined by DAPI staining after 16 h.
As expected, 60–70% of cells of either genotype became
apoptotic in suspension (Fig. 6 B), while only 2% of either
Figure 2. Proliferative index of wild-type and a1-null embryonic dermal fibroblasts. (A) Mid cross-section of 16.5 embryos were stained
with anti-PCNA antibodies, and subsequently counterstained with hematoxylin. Note the higher number of dermal PCNA-positive cells
in the wild-type (WT) dermis, as compared with their a1-null (KO) counterparts. (B) The dermal proliferative index (number of PCNA
positive cells/total number of cells 3 100) of three wild-type and three a1-null 16.5 embryos was determined by random evaluation of 12
different 403 microscopic fields for each sample, counting a minimum of 900 cells around the entire circumference of embryonal der-
mis. Bars and errors indicate the mean and standard deviation. Differences between wild-type and a1-null groups were significant with
P , 0.05 by Student’s t test. Bar, 30 mm. 
Figure 3. Proliferative index of wild-type and a1-null adult fibro-
blasts in wounded dermis. (A) Sections of wild-type (WT) and
a1-deficient (KO) wounded skin, 12 d after incision and primary
closure, stained with anti-PCNA antibodies, and subsequently
counterstained with hematoxylin. The proportion of PCNA-posi-
tive cells in the dermal wound (seen as dark nuclei in the micro-
graph) was similar in wild-type and a1-null animals. (B) The der-
mal proliferative index (number of PCNA positive cells/total
number of cells 3 100) was determined by random evaluation of
3 different 403 microscopic fields for each sample, counting a
minimum of 300 cells. Bars and errors indicate the mean and
standard deviation. Bar, 100 mm.Pozzi et al. a1b1 Integrin and Proliferation 591
genotype plated on fibrinogen became apoptotic (Fig. 6, A
and B). On collagenous matrices however (Fig. 6, A and
B), a1-null EFs showed a sevenfold increase in apoptosis
over wild-type EFs.
In conclusion, the in vitro results are in agreement with
the in vivo observation, and suggest that the reduction in
dermal fibroblast number observed in a1-null mice is
caused by a combination of reduced survival and reduced
proliferation.
a1-null Embryonic Fibroblasts Fail to Activate the 
Adaptor Protein Shc When Plated on Collagens
The differences in proliferation between a1-null and wild-
type EFs on collagen substrata suggests that the interac-
tion between integrin a1b1 and collagens is required for
the activation of a specific survival/proliferation pathway.
It has been shown (Wary et al., 1996) that activation of
a1b1 causes recruitment and tyrosine phosphorylation
of the adaptor protein Shc. This protein, via recruitment
of Grb2 and activation of the the Ras-MAP kinase path-
way, cooperates with mitogens to mediate cell survival and
proliferation. Based on this observation, we investigated
the activation of Shc by wild-type and a1-deficient EFs
upon adhesion on different substrata. We have previously
shown that a1-deficient fibroblasts fail to adhere to col-
lagen IV (Gardner et al., 1996). Thus, to analyze the con-
tribution of this molecule in the activation of Shc via a1 in-
tegrin,  a1-deficient cells were plated on a mixture of
collagen I and IV, or on collagen I alone, and the level of
Shc activation compared with that observed in their nor-
mal counterparts. With these substrata, the extent of adhe-
sion of wild-type and a1-null cells is indistinguishable.
Cells kept in suspension, or plated on fibronectin were
used, respectively, as negative and positive controls for ac-
tivation of the Shc pathway. Cell lysates were immunopre-
cipitated with anti-Shc antibody and subjected to immuno-
blotting with anti-phosphotyrosine antibody to determine
Shc activation, with anti-Grb2 antibody to examine re-
cruitment of Grb2, and with anti-Shc antibody to check for
equal loading. Cell lysates were also immunoprecipitated
with anti-Erk2 antibody and subjected to in vitro kinase
assay to determine MAPK activation. As expected, EFs of
both genotype failed to cause Shc phosphorylation when
kept in suspension (Fig. 7 B), despite containing normal
Figure 4. Growth of wild-type
and a1-deficient embryonic fi-
broblasts on different substrata.
10 3 104 log phase wild-type (u)
and a1-null (d) EFs were plated
in presence of 2% FCS (A) or
10% FCS (B) on 24-well plates
uncoated, or coated with fibrin-
ogen (10 mg/ml), collagen I (100
mg/ml), or a mixture of collagen
I (100 mg/ml) and IV (30 mg/ml).
Two wells per group for each
treatment were counted at the
time point indicated. This experi-
ment is representative of three re-
peated experiments. Note the re-
duced growth of a1-null EFs, on
collagen-coated dishes, as com-
pared with the wild-type cells.
Bars and errors indicate the mean
and the higher number from two
dishes per each group.
Figure 5. Profilerative index of wild-type and a1-null embryonic
fibroblasts in vitro. (A) EFs were plated in presence of 2% FCS
onto dishes uncoated or coated with fibrinogen (10 mg/ml), col-
lagen I (100 mg/ml), or a mixture of collagen I (100 mg/ml) and
collagen IV (30 mg/ml). 24 h after plating, cells were labeled with
10 mM BrdU (Sigma Chemical Co.), and incubated for a further 24 h.
After staining with anti-BrdU mAbs, the Brdu labeling index
(positive cells/total number of counted cells 3 100) was deter-
mined by random evaluation of five different 403 microscopic
fields for each duplicate sample, counting a minimum of 200 cells.
Bars and errors indicate the mean and standard deviation. The
differences seen between wild-type and a1-null groups on col-
lagens are significant with P , 0.05 using a Student’s t-test on the
10 microscopic fields counted for each sample. (B) S phase entry
of wild-type and a1-null embryonic fibroblasts after serum star-
vation. Passage 4 EFs were starved for 24 h, before plating on
various substrata in the presence of 2% FCS. After 12 h cells
were recovered by trypsinization, and subjected to FACS® analy-
sis as described in Materials and Methods. Bars indicate the mean
and error bars the distance to the higher value for each pair of
samples analyzed. TC, tissue culture; FN, fibronectin; FIB, fibrin-
ogen; CI, collagen I; CI 1 IV, collagen I 1 IV; ST, serum starved.The Journal of Cell Biology, Volume 142, 1998 592
levels of protein (Fig. 7 A). Consequently, no recruitment
of Grb 2 (Fig. 7 C), or activation of MAP kinase (Fig. 7 D)
was observed. In contrast, both cell types activated Shc
protein and its related downstream cascade, when plated
on fibronectin (Fig. 7, A–D). Striking differences in the ac-
tivation of Shc, and its related downstream events, how-
ever, were observed between wild-type and a1-null EFs
after adhesion on collagen I or a mixture of collagen I and
IV. a1-null EFs entirely failed to activate Shc when plated
for 1 h on substrata of collagen I or a mixture of collagen I
and IV in contrast to wild-type cells (Fig. 7 B). The failure
to activate Shc by a1-deficient cells was accompanied by a
downstream deficiency in recruitment of Grb 2 (Fig. 7 C)
and subsequent MAPK activation (Fig. 7 D). Taken to-
gether with the growth deficiency we have observed in a1-
null EFs on collagen substrata (Fig. 4), this finding demon-
strates that a1 collagen receptor has a unique and pivotal
role in regulating cell survival and proliferation on collage-
nous matrices.
Discussion
In this study we have used integrin a1–deficient mice to in-
vestigate the role of a1b1 receptor in the regulation of
dermal fibroblast growth. We provide evidence that inte-
grin a1b1, the major collagen-binding receptor, controls
the proliferation of dermal fibroblasts both in vivo and in
vitro, and that cell survival and proliferation on collagen
substrata are mediated specifically and uniquely by inte-
grin a1b1.
In fibroblasts integrin a1b1 regulates different functions
upon binding to collagen matrices. One of these is the regu-
lation of collagen synthesis. We have found that the a1-null
animals lack negative feedback regulation of collagen syn-
thesis and synthesize excess dermal collagen in vivo. This is
not apparent morphologically, as the animals also show in-
creased synthesis of collagenases, and thus compensate ex-
cess synthesis with increased breakdown (Gardner, H., A.
Broberg, A. Pozzi, J. Heino, submitted manuscript). This
dysregulation appears to cause a small reduction in tensile
strength of intact skin (Davidson, J., unpublished results).
Another function of integrin a1b1, analyzed in the
present paper, is the control of cell growth and prolifera-
tion. We have shown that fibroblast growth, proliferation,
and survival are events mediated by integrin a1 activation
of the Ras-MAPK pathway, as previously suggested by the
in vitro studies of Wary et al. (1996). We have demon-
strated that when plated on collagen matrices, a1-deficient
fibroblasts fail to activate the adaptor protein Shc, show-
ing a reduced cell proliferation compared with their wild-
type counterparts. This observation is complemented by
our observation of dermal fibroblasts in vivo. Analysis of
Figure 6. Apoptotic index of
wild-type and a1-null EFs in
vitro. (A) EFs were plated in
absence of serum on cover-
slips coated with collagen I (20
mg/ml) or fibrinogen (10 mg/
ml). 16 h after plating, cover-
slips were washed to remove
unattached cells, fixed, and
then stained with 0.5 mg/ml
DAPI. Chromatin condensa-
tion was used to score posi-
tive apoptotic cells. Note the
higher number of apoptotic-
positive cells in a1-null EFs
as compared with wild-type cells when plated on collagen matrix.
(B) The apoptotic index (cells with condensed chromatin/total
number of counted cells 3 100) of EFs, kept in suspension or
plated in dishes coated as indicated, was determined by random
evaluation of five different 403 microscopic fields for each dupli-
cate sample, counting a minimum of 300 cells. Bars and errors in-
dicate the mean and standard deviation. Significant differences
were seen between wild-type and a1-null groups on collagens
with P , 0.05 using a Student’s t-test on the 10 microscopic fields
counted for each sample. SUSP, suspension; FIB, fibrinogen; CI,
collagen I; C I 1 IV, collagen I 1 IV. Bar, 40 mm. 
Figure 7. a1-null EFs fail to recruit and activate Shc and subse-
quent downstream events when plated on collagens. EFs were se-
rum starved for 8 h and then trypsinized. Cells were then resus-
pended in DME/0.1% BSA and kept at room temperature for 30
min. They were then either left in suspension or plated on dishes
coated with fibronectin (10 mg/ml), collagen I (20 mg/ml), or a
mixture of collagen I (20 mg/ml) and IV (10 mg/ml). After 1 h at
378C, cells were lysed and an equal amount of proteins were im-
munoprecipitated with anti-Shc polyclonal antibody (A–C), and
subjected to immunoblotting with anti-Shc polyclonal antibody
(A), anti–P-Tyr mAb (B), or anti–Grb-2 mAb (C). In D, equal
amount of proteins were immunoprecipitated with anti-ERK2
polyclonal antibody and subjected to in vitro kinase assay with
myelin basic protein as substrate. Note that when plated on col-
lagens, a1-null EFs fail to phosphorylate Shc (B) or to activate
events downstream of Shc (C and D), despite containing normal
level of Shc protein (A). SUSP, suspension; FN, fibronectin; CI,
collagen I; C I 1 IV, collagen I 1 IV.Pozzi et al. a1b1 Integrin and Proliferation 593
embryonic skin indicates that wild-type dermal fibroblasts
proliferate more than their a1-null counterparts, support-
ing the hypothesis that a1 integrin plays a role in control-
ling cell growth. This difference in cell growth was not evi-
dent in adult skin, probably because the overall rate of
proliferation in the adult dermis is negligible. Thus, our
observation that adult a1-null dermis is hypocellular as
compared with wild-type can be interpreted as the result
of a defective proliferation of a1-deficient fibroblasts dur-
ing embryogenesis, although a very slowly accumulated
deficiency in proliferation in the adult a1-null dermis can-
not be ruled out by our studies.
To induce fibroblast proliferation in adult dermis, we
have performed dermal wound healing experiments on
wild-type and a1-deficient animals. 12 d after the incision,
no differences in the proliferative index of dermal fibro-
blasts of either genotype were evident in the wounded
area. This may be explained by the fact that, during the
first stages of wound healing fibrinogen, rather than col-
lagen, is the major ECM component to be deposited in the
wound, accompanied by local synthesis of fibronectin.
These molecules could regulate, via avb3 and a5b1 inte-
grins, respectively, cell growth of both wild-type and a1-
null fibroblasts, reducing or eliminating the differences in
cell proliferation visible on collagen substrata. In this con-
text, we have observed that when plated on fibronectin
both wild-type and a1-deficient embryonic fibroblasts ac-
tivate the Shc pathway, and show a similar growth profile.
Fibroblasts express a5b1 (Dalton et al., 1992) and it has
been shown that activation of a5b1 leads to recruitment of
Shc (Wary et al., 1996). Similarly, our results on the prolif-
erative index of wild-type and a1-deficient hepatocytes
suggest the possibility that different ECM–integrin inter-
actions could take place in these cells, and be dominant
over the lack of a1 integrin in the control of cell survival
and proliferation. In fact, given the variety of possible
ligand integrin interactions, which do promote prolifera-
tion, it is striking that embryonic dermal fibroblasts have a
perceptible dependence on the a1–collagen interaction for
proliferation in vivo.
Our in vitro observation that activation of Shc on collage-
nous matrices occurs only in wild-type cells indicates that, al-
though fibroblasts express three collagen receptors a1b1,
a2b1, and a3b1 (Zutter and Santoro, 1990; Gardner et al.,
1996), a1b1 integrin is the only one of these able to deliver a
specific collagen-induced signal to the Ras-MAPK pathway,
via Shc activation. Recently, it has been observed that the
Shc phosphotyrosine binding domain can also bind to the
DDR tyrosine kinase receptor after collagen stimulation and
receptor autophosphorylation (Vogel et al., 1997), suggest-
ing the possibility that DDR and integrin receptors may co-
operate in the regulation of cell survival and proliferation.
However, the observation that the MAPK pathway is not
activated upon binding of DDR to collagen (Vogel et al.,
1997), strongly supports the hypothesis that collagen-
dependent proliferation is mainly mediated via activation
of integrin a1b1.
Integrin a1b1 is only one of a larger family of integrins
able to activate Shc. This subset of receptors includes inte-
grin a5b1, the receptor involved in the control of cell cycle
progression and proliferation in human umbilical vein en-
dothelial cells (HUVECs) upon binding to fibronectin
(Wary et al., 1996) and a6b4, which plays a role in regu-
lating keratinocyte proliferation, via activation of the
same Ras-MAPK pathway (Maniero et al., 1997). Thus,
the same adaptor molecule, activated by different inte-
grin–ligand interaction (a1b1–collagen, a5b1–fibronectin,
a6b4–laminin, and avb3–fibrinogen) is able to regulate
cell growth of different cell types. It is interesting to note
in this context that integrin a5–null embryos, which die in
mid-gestation, show a failure of proliferation of neural
crest derivatives (Goh et al., 1997), suggesting that these
may depend upon the a5b1–fibronectin interaction for
proliferation in a manner analagous to the a1b1–collagen
interaction in the dermis.
Whereas activation of Shc leads to cell growth and pro-
liferation, adhesion mediated by integrins not linked to
Shc appears unable to prevent apoptotic death (Wary et al.,
1996). We have observed that a1-null cells, although able
to adhere on collagen I or a mixture of collagen I and IV
indistinguishably from their wild-type counterparts, are
more susceptible to apoptosis, indicating that a1 integrin
effects both fibroblast proliferation and survival. Shc sig-
naling may contribute to protection from apoptosis by ac-
tivating Ras and thereby PI-3 kinase, as activated forms of
Ras and PI-3 kinase protect from suspension induced apop-
tosis (Khwaja et al., 1997). FAK activation by various inte-
grins has also been implicated in cell survival (Frisch and
Ruoslahti, 1997; Hungerford et al., 1996), and may too act
via PI-3 kinase (Chen and Guan, 1994).
It is striking that the adhesive function of integrin a1b1
is apparently dispensable, permitting normal morphogene-
sis in the null, it is its role in regulating cell proliferation
which, in its absence, gives rise to a perceptible phenotype
in vivo. The observation that only one of the three dermal
fibroblast collagen receptors specifically controls prolifer-
ation suggests that different integrin receptors for a single
ligand accomplish different and unique functions within a
single cell. Such functions may be quite distinct from, and
in some instances more important than, their adhesive
functions.
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Note Added in Proof. A recent study provides further evidence that inte-
grin-mediated Shc signaling regulates cell proliferation in vivo (Murgia,
C., P. Blaikie, N. Kim, M. Dans, H.T. Petrie, and F.G. Giancotti. 1998.
EMBO (Eur. Mol. Biol. Organ.) J. In press).
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